CN104169268A - 三环砜化合物及其制备和使用方法 - Google Patents

三环砜化合物及其制备和使用方法 Download PDF

Info

Publication number
CN104169268A
CN104169268A CN201380014172.8A CN201380014172A CN104169268A CN 104169268 A CN104169268 A CN 104169268A CN 201380014172 A CN201380014172 A CN 201380014172A CN 104169268 A CN104169268 A CN 104169268A
Authority
CN
China
Prior art keywords
alkyl
group
alkoxy
hydrogen
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380014172.8A
Other languages
English (en)
Chinese (zh)
Inventor
T·D·帕林
H·J·戴克
S·M·克兰普
R·赞勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Larimar Therapeutics Inc
Original Assignee
Zafgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zafgen Inc filed Critical Zafgen Inc
Publication of CN104169268A publication Critical patent/CN104169268A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
CN201380014172.8A 2012-01-18 2013-01-17 三环砜化合物及其制备和使用方法 Pending CN104169268A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261587825P 2012-01-18 2012-01-18
US61/587,825 2012-01-18
PCT/US2013/021914 WO2013109735A1 (en) 2012-01-18 2013-01-17 Tricyclic sulfone compounds and methods of making and using same

Publications (1)

Publication Number Publication Date
CN104169268A true CN104169268A (zh) 2014-11-26

Family

ID=47710307

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380014172.8A Pending CN104169268A (zh) 2012-01-18 2013-01-17 三环砜化合物及其制备和使用方法

Country Status (10)

Country Link
US (1) US9440943B2 (enExample)
EP (1) EP2804856B1 (enExample)
JP (1) JP2015509102A (enExample)
KR (1) KR20140112566A (enExample)
CN (1) CN104169268A (enExample)
AU (1) AU2013209719A1 (enExample)
BR (1) BR112014017780A8 (enExample)
CA (1) CA2861381A1 (enExample)
MX (1) MX2014008705A (enExample)
WO (1) WO2013109735A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112898202A (zh) * 2021-01-27 2021-06-04 中国科学院上海有机化学研究所 一种杂环基并环丙烷化合物、合成方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
KR20140040739A (ko) 2011-05-06 2014-04-03 자프겐 인크. 삼환식 피라졸 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
WO2012154676A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Partially saturated tricyclic compounds and methods of making and using same
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
EP2846792B1 (en) 2012-05-08 2018-08-15 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
JP6177888B2 (ja) 2012-05-09 2017-08-09 ザフゲン，インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
JP6169716B2 (ja) 2012-11-05 2017-07-26 ザフゲン，インコーポレイテッド 肝疾患を治療する方法
WO2014071363A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
US9597309B2 (en) 2013-03-14 2017-03-21 Zafgen, Inc. Methods of treating renal disease and other disorders
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
MX391461B (es) * 2016-03-22 2025-03-21 Helsinn Healthcare Sa Ureas bencenosulfonil-asimetricas y usos medicos de las mismas.
CN107056742A (zh) * 2017-04-20 2017-08-18 牛永友 一种治疗哮喘的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065883A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2011044506A2 (en) * 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164410A (en) 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
PH26256A (en) 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
KR0138530B1 (ko) 1988-09-01 1998-05-15 우메모또 요시마사 푸마길롤 유도체
US5180738A (en) 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
DE69001187T2 (de) 1989-03-06 1993-07-08 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
US5288722A (en) 1989-03-06 1994-02-22 Takeda Chemical Industries, Ltd. 6-amino-6-desoxyfumagillols, production and use thereof
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US6017954A (en) 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
EP0415294A3 (en) 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (enExample) 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE69330690T2 (de) 1992-01-30 2002-06-20 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe
DE69311278T2 (de) 1992-12-16 1997-10-30 Takeda Chemical Industries Ltd Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
HU224028B1 (hu) 1995-03-27 2005-05-30 Assistance Publique-Hopitaux De Paris Fumagillol és származékai alkalmazása bélfertőzések kezelésére szolgáló gyógyszerek előállítására
WO1997013509A1 (en) 1995-10-11 1997-04-17 Fujisawa Pharmaceutical Co., Ltd. Vascular permeation inhibitor
EP0799616A1 (en) 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
WO1998005293A2 (en) 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
DK0973392T3 (da) 1997-03-04 2004-03-29 Monsanto Co Divalente sulfonyl-aryl eller heteroarylhydroxamsyreforbindelser
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
JP2002502814A (ja) 1997-10-31 2002-01-29 チルドレンズ・メディカル・センター・コーポレイション 血管化した正常組織の大きさおよび増殖の調節のための方法
WO1999032433A1 (en) 1997-12-23 1999-07-01 Warner-Lambert Company Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357541B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
JP2000116337A (ja) 1998-10-09 2000-04-25 Nippon Shokuhin Kako Co Ltd ペットフード
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EE200100558A (et) 1999-04-28 2002-12-16 Aventis Pharma Deutschland Gmbh Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
ES2207528T3 (es) 1999-07-15 2004-06-01 Basf Aktiengesellschaft Procedimiento para la preparacion de esteres de acido 5-y/o 6-sustituido-2-hidroxibenzoico.
EP1223932A4 (en) 1999-10-01 2003-01-15 Smithkline Beecham Corp COMPOUNDS AND METHODS
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
AR030631A1 (es) 2000-09-29 2003-08-27 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
AU2002239479B2 (en) 2000-11-01 2006-11-09 Praecis Pharmaceuticals Incorporated Peptides as Met-AP2 inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
WO2002059124A2 (en) 2000-12-20 2002-08-01 Bristol-Myers Squibb Company Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
WO2002078699A1 (en) 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods
US20020183242A1 (en) 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
DE60233420D1 (de) 2001-09-27 2009-10-01 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040067266A1 (en) 2002-10-07 2004-04-08 Toppo Frank R. Weight loss compound
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040157836A1 (en) 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US20040068012A1 (en) 2002-10-08 2004-04-08 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
EA200600203A1 (ru) 2003-08-08 2006-08-25 Янссен Фармацевтика, Н. В. Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
PE20050948A1 (es) 2003-09-09 2005-12-16 Japan Tobacco Inc Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
PL1697378T3 (pl) 2003-12-22 2008-04-30 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzoizoksazole i 1,2-benzoizotiazole oraz ich wytwarzanie i zastosowania
US20050239878A1 (en) 2003-12-29 2005-10-27 Praecis Pharmaceuticals, Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
KR100552043B1 (ko) 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
AU2005245401A1 (en) 2004-05-12 2005-12-01 Chemocentryx Aryl sulfonamides
CA2571683A1 (en) 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
MX2007003623A (es) 2004-09-24 2007-09-11 Johnson & Johnson Compuestos sulfonamida.
JP2008528574A (ja) 2005-01-26 2008-07-31 チョン クン ダン ファーマシューティカル コープ． フマギロール誘導体またはフマギロール誘導体の製造方法およびこれを含む医薬用組成物
FR2886855B1 (fr) 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
WO2006138475A2 (en) 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
WO2007076348A2 (en) 2005-12-23 2007-07-05 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases
WO2008008374A2 (en) 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
DE102007020492A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
CA2690244C (en) 2007-06-26 2016-08-09 Ofra Benny-Ratsaby Metap-2 inhibitor polymersomes for therapeutic administration
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
BRPI0820229A2 (pt) 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
ATE506359T1 (de) 2007-11-30 2011-05-15 Bayer Schering Pharma Ag Heteroaryl-substituierte piperidine
WO2010009374A1 (en) 2008-07-18 2010-01-21 Zafgen, Inc. Methods of treating an overweight or obese subject
EP2350012B1 (en) 2008-10-06 2017-06-28 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
WO2010048499A1 (en) 2008-10-24 2010-04-29 Wake Forest University Platinum acridine anti-cancer compounds and methods thereof
WO2010065881A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
US20120010290A1 (en) 2008-12-04 2012-01-12 Vath James E Methods of Treating an Overweight or Obese Subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
WO2011150338A1 (en) 2010-05-27 2011-12-01 Zafgen Corporation Methods of treating obesity
US20120020647A1 (en) 2010-07-21 2012-01-26 Rovi Technologies Corporation Filtering repeated content
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
US8428080B2 (en) 2010-09-16 2013-04-23 Apple Inc. Method to control reconfiguration of multiple radio access bearers in a wireless device
WO2012051318A1 (en) 2010-10-12 2012-04-19 Zafgen Corporation Sulphonamide compounds and methods of making and using same
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
CN103402989B (zh) 2011-01-26 2016-04-06 扎夫根股份有限公司 四唑化合物及其制备和使用方法
WO2012154676A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Partially saturated tricyclic compounds and methods of making and using same
KR20140040739A (ko) 2011-05-06 2014-04-03 자프겐 인크. 삼환식 피라졸 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
US9090640B2 (en) 2011-09-02 2015-07-28 Ulrich Bierbach Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
WO2014071363A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065883A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2011044506A2 (en) * 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GARY T. WANG ET AL.,: "Lead optimization of methionine aminopeptidase-2 (MetAP2) inhibitors containing sulfonamides of 5,6-disubstituted anthranilic acids", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112898202A (zh) * 2021-01-27 2021-06-04 中国科学院上海有机化学研究所 一种杂环基并环丙烷化合物、合成方法

Also Published As

Publication number Publication date
WO2013109735A1 (en) 2013-07-25
KR20140112566A (ko) 2014-09-23
AU2013209719A1 (en) 2014-08-07
EP2804856B1 (en) 2017-03-15
EP2804856A1 (en) 2014-11-26
BR112014017780A8 (pt) 2017-07-11
CA2861381A1 (en) 2013-07-25
MX2014008705A (es) 2015-02-05
US9440943B2 (en) 2016-09-13
BR112014017780A2 (enExample) 2017-06-20
US20150119456A1 (en) 2015-04-30
JP2015509102A (ja) 2015-03-26

Similar Documents

Publication Publication Date Title
EP2804856B1 (en) Tricyclic sulfone compounds and methods of making and using same
US9321740B2 (en) Tetrazole compounds and methods of making and using same
EP2804866B1 (en) Tricyclic sulfonamide compounds and methods of making and using same
JP6035327B2 (ja) 三環式ピラゾールスルホンアミド化合物ならびにその製造および使用方法
EP2917197B1 (en) Tricyclic compounds and methods of making and using same
CN104918928A (zh) 三环化合物及其制备方法和用途
CN104203954B (zh) 三环磺酰胺化合物及其制备和使用方法
AU2012211250A1 (en) Tetrazole compounds and methods of making and using same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141126

WD01 Invention patent application deemed withdrawn after publication